

Host



KDDF

Korea Drug Development Fund

2024 Global Biotech Showcase *for Investors*

July 18 - 19, 2024

Grand InterContinental Seoul Parnas

User Guide

<https://gbs.kddf.org>

1. Account Login

- Please visit <https://gbs.kddf.org> to start
- **Invited VCs:** Please sign up for a new account.
- **Re-visiting VCs:** If you participated last year, please log in with your existing account. Your password has been reset to **a123456**. Change your password immediately after logging in for security purposes.
 - ✂ If you forgot your email, please contact the secretariat by email at rsvp.topplan@gmail.com.

[Pipeline](#) / [Favorites List](#) / [My Page](#) / [Log In](#)

Log In

Email

Password

LOGIN

[Forget your ID/Password?](#)

Sign up

2. Navigating the Pipeline

- Once logged in, locate the **'Pipeline'** at the top of the page.
- Click on the number displayed to review the list of KDDF's R&D Pipeline and details in the selected category.
- To view more stages of the pipeline, scroll sideways.

Pipeline

Favorites List


My Page

Log Out

KDDF R&D Pipeline

No. of project : 345

R&D Pipeline by Development Stage & Therapeutic Area



3. Downloading Project Details and Selecting Favorites









- If you find an interesting project, click on the PDF file icon to download detailed information.
- Click on the favorite icon(♡) to mark companies as favorites for potential 1:1 partnering.
 - ✓ Please select between 15 to 20 favorites to arrange meeting schedules.
 - ✓ The deadline for making your selections is **June 7th, Friday.**

※ 2024 new projects will be updated on June 5th.
We will email you the details on the new projects in a separate ZIP file by June 5th.
If you are interested in one of the new projects, please contact rsvp.topplan@gmail.com by June 7th.

Pipeline / Favorites List / My Page / Log Out

KDDF R&D Pipeline

Oncology - Phase1 (15)





	Modality	Indication	Targets	Stage	Company	Project No.	Detail	Favorite
1	Autologous 4th generation GPC3 CAR.T clinical study for advanced hepatocellular carcinoma							
	Gene Therapy	Liver cancer	GPC3	Phase 1	Eutilex Co.,Ltd.	RS-2023-00283610		
2	Phase 1 clinical Study of ENPP1 inhibitory Immunotherapy TXN10128							
	Small Molecules	Solid tumor	ENPP1	Phase 1	Txinno Bioscience Inc.	RS-2023-00282830		
3	TC011: Clinical Phase I Trial Evaluating Safety, Pharmacokinetics, DLT, MTD, Efficacy and RP2D of TC011, a CD19.Targeted CAR.T Therapyin Relapsed or Refractory B.Cell Non.Hodgkin Lymphoma Patients							
	Gene Therapy	B cell lymphoma	CD19	Phase 1	TICAROS	RS-2023-00258721		
4	Phase I Clinical Study of WM-S1-030 in patients with advanced or metastatic solid tumor							
	Small Molecules	Colorectal cancer	mutant RON	Phase 1	Wellmarkerbio Co., Ltd.	RS-2023-00219060		
5	A Phase 1b/2a Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of TU2218, an oral TGFβR Serine/Threonine Kinase Inhibitor, Administered in Combination with Pembrolizumab in Patients with Advanced Solid Tumors							
	Small Molecules	Solid Tumor	TGFβR1	Phase 1	Tium BIO	RS-2022-00167091		

4. Managing Your Favorites List

- Navigate to the 'Favorites List' category to view and modify your list of selected companies for 1:1 partnering.
- Your 1:1 partnering schedule will be informed to you once matches are made.
- The meeting schedule will be determined based on your selected preferences.

Pipeline / **Favorites List** / My Page / Log Out

Favorites List

	Modality	Indication	Targets	Stage	Company	Project No.	Detail	Favorite
1	TC011: Clinical Phase I Trial Evaluating Safety, Pharmacokinetics, DLT, MTD, Efficacy and RP2D of TC011, a CD19.Targeted CAR.T Therapyin Relapsed or Refractory B.Cell Non.Hodgkin Lymphoma Patients							
	Gene Therapy	B cell lymphoma	CD19	Phase 1	TICAROS	RS-2023-00258721		
2	Autologous 4th generation GPC3 CAR.T clinical study for advanced hepatocellular carcinoma							
	Gene Therapy	Liver cancer	GPC3	Phase 1	Eutilex Co.,Ltd.	RS-2023-00283610		

Host



KDDF

Korea Drug Development Fund

2024 Global Biotech Showcase *for Investors*

July 18 - 19, 2024

Grand InterContinental Seoul Parnas

Contact :

rsvp.topplan@gmail.com